The past and future of CD33 as therapeutic target in acute myeloid leukemia.

[1]  L. Weiner,et al.  CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets. , 2014, Blood.

[2]  A. Henn,et al.  Preclinical Characterization of AMG 330, a CD3/CD33-Bispecific T-Cell–Engaging Antibody with Potential for Treatment of Acute Myelogenous Leukemia , 2014, Molecular Cancer Therapeutics.

[3]  D. Bonnet,et al.  Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo , 2014, Leukemia.

[4]  E. Estey,et al.  Declining rates of treatment-related mortality in patients with newly diagnosed AML given ‘intense’ induction regimens: a report from SWOG and MD Anderson , 2014, Leukemia.

[5]  R. Kischel,et al.  Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML. , 2014, Blood.

[6]  W. Hiddemann,et al.  CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330. , 2014, Blood.

[7]  G. Ehninger,et al.  Costimulation improves the killing capability of T cells redirected to tumor cells expressing low levels of CD33: description of a novel modular targeting system , 2014, Leukemia.

[8]  M. Vignetti,et al.  Sequential combination of gemtuzumab ozogamicin and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia: results of a randomized phase III trial by the EORTC and GIMEMA consortium (AML-17). , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  T. Fry,et al.  T-cell adoptive immunotherapy for acute lymphoblastic leukemia. , 2013, Hematology. American Society of Hematology. Education Program.

[10]  S. Raimondi,et al.  Negative Prognostic Impact Of High CD33 Expression Is Negated With The Use Of Gemtuzumab Ozogamicin: A Report From The Children’s Oncology Group , 2013 .

[11]  E. Estey,et al.  Phase I Trial Of The Targeted Alpha-Particle Nano-Generator Actinium-225 (225Ac)-Lintuzumab (Anti-CD33) In Combination With Low-Dose Cytarabine (LDAC) For Older Patients With Untreated Acute Myeloid Leukemia (AML) , 2013 .

[12]  E. Estey,et al.  The Addition Of Gemtuzumab Ozogamicin (GO) To Induction Chemotherapy Reduces Relapse and Improves Survival In Patients Without Adverse Risk Karyotype: Results Of An Individual Patient Meta-Analysis Of The Five Randomised Trials , 2013 .

[13]  S. Raimondi,et al.  Gemtuzumab Ozogamicin (GO) In Children With De Novo Acute Myeloid Leukemia (AML) Improves Event-Free Survival (EFS) By Reducing Relapse Risk – Results From The Randomized Phase III Children’s Oncology Group (COG) Trial, AAML0531 , 2013 .

[14]  Ira Mellman,et al.  Antibody Therapeutics in Cancer , 2013, Science.

[15]  I. Bernstein,et al.  SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. , 2013, Blood.

[16]  B. Löwenberg,et al.  Gemtuzumab ozogamicin in acute myeloid leukemia: a remarkable saga about an active drug. , 2013, Blood.

[17]  R. Larson,et al.  A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. , 2013, Blood.

[18]  E. Estey,et al.  Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicin. , 2013, Frontiers in bioscience.

[19]  A. Takeshita.  Efficacy and resistance of gemtuzumab ozogamicin for acute myeloid leukemia , 2013, International Journal of Hematology.

[20]  Bin Zhang,et al.  Targeting Natural Killer Cells to Acute Myeloid Leukemia In Vitro with a CD16 × 33 Bispecific Killer Cell Engager and ADAM17 Inhibition , 2013, Clinical Cancer Research.

[21]  A. Mackensen,et al.  T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct , 2013, Leukemia.

[22]  H. Kantarjian,et al.  Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced myeloid malignancies , 2013, Haematologica.

[23]  G. Ehninger,et al.  Redirection of T cells with a first fully humanized bispecific CD33–CD3 antibody efficiently eliminates AML blasts without harming hematopoietic stem cells , 2013, Leukemia.

[24]  R. Hills,et al.  The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison , 2013, Leukemia.

[25]  C. Perry,et al.  Gemtuzumab Ozogamicin , 2012, Drugs.

[26]  H. Einsele,et al.  Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. , 2012, Blood.

[27]  William J Kelton,et al.  Engineering Anti-AML Antibodies for Improved NK Cell ADCC , 2012 .

[28]  K. Heider,et al.  A Novel Fc-Engineered Antibody to CD33 with Enhanced ADCC Activity for Treatment of AML , 2012 .

[29]  H. Einsele,et al.  Anti-CD19 BiTE Blinatumomab Induces High Complete Remission Rate and Prolongs Overall Survival in Adult Patients with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL) , 2012 .

[30]  E. Estey,et al.  Gemtuzumab ozogamicin: time to resurrect? , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  M. Konopleva,et al.  Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia. , 2012, Clinical lymphoma, myeloma & leukemia.

[32]  C. Craddock,et al.  Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  I. Bernstein,et al.  Acute myeloid leukemia stem cells and CD33-targeted immunotherapy. , 2012, Blood.

[34]  J. Foran.  Gemtuzumab: time to bring back on the market? , 2012, Clinical advances in hematology & oncology : H&O.

[35]  H. Dombret,et al.  Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study , 2012, The Lancet.

[36]  E. Estey.  Treatment of AML: resurrection for gemtuzumab ozogamicin? , 2012, The Lancet.

[37]  P. Crocker,et al.  CD33‐related siglecs as potential modulators of inflammatory responses , 2012, Annals of the New York Academy of Sciences.

[38]  J. Kwekkeboom,et al.  Defining Early Human NK Cell Developmental Stages in Primary and Secondary Lymphoid Tissues , 2012, PloS one.

[39]  A. Lawson,et al.  In Vitro and In Vivo Antitumor Effect of Anti-CD33 Chimeric Receptor-Expressing EBV-CTL against CD33+ Acute Myeloid Leukemia , 2012, Advances in hematology.

[40]  H. Dombret,et al.  Fractionated doses of gemtuzumab ozogamicin with escalated doses of daunorubicin and cytarabine as first acute myeloid leukemia salvage in patients aged 50–70‐year old: A phase 1/2 study of the acute leukemia French association , 2012, American journal of hematology.

[41]  S. Ha,et al.  Gemtuzumab ozogamicin as postconsolidation therapy does not prevent relapse in children with AML: results from NOPHO-AML 2004. , 2011, Blood.

[42]  I. Bernstein,et al.  Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML. , 2008, Blood.

[43]  D. Hoelzer,et al.  Chemoimmunotherapy in acute lymphoblastic leukemia. , 2012, Blood reviews.

[44]  G. Riethmüller.  Symmetry breaking: bispecific antibodies, the beginnings, and 50 years on. , 2012, Cancer immunity.

[45]  A. Vekhoff,et al.  Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia , 2012, Investigational New Drugs.

[46]  G. Ehninger,et al.  Unexpected recombinations in single chain bispecific anti-CD3-anti-CD33 antibodies can be avoided by a novel linker module. , 2011, Molecular immunology.

[47]  B. Wood,et al.  Lintuzumab and Low-Dose Cytarabine Compared to Placebo and Low-Dose Cytarabine in Patients with Untreated Acute Myeloid Leukemia (AML) 60 Years and Older: Results of a Randomized, Double-Blinded Phase 2b Study, , 2011 .

[48]  A. Korman,et al.  BMS-936564/MDX-1338: A Fully Human Anti-CXCR4 Antibody Induces Apoptosis In Vitro and Shows Anti Tumor Activity In Vivo , 2011 .

[49]  C. Volteau,et al.  Addition of Gemtuzumab Ozogamycin to Chemotherapy Improves Event-Free Survival but Not Overall Survival of AML Patients with Intermediate Cytogenetics Not Eligible for Allogeneic Transplantation. Results of the GOELAMS AML 2006 IR Study , 2011 .

[50]  A. Ricart.  Antibody-Drug Conjugates of Calicheamicin Derivative: Gemtuzumab Ozogamicin and Inotuzumab Ozogamicin , 2011, Clinical Cancer Research.

[51]  R. Foà,et al.  High CD33 expression levels in acute myeloid leukemia cells carrying the nucleophosmin (NPM1) mutation , 2011, Haematologica.

[52]  B. Coiffier,et al.  SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma. , 2011, Blood.

[53]  A. Lawson,et al.  In Vitro Comparison of Three Different Chimeric Receptor-modified Effector T-cell Populations for Leukemia Cell Therapy , 2011, Journal of immunotherapy.

[54]  D. Bigner,et al.  Bispecific antibodies engage T cells for antitumor immunotherapy , 2011, Expert opinion on biological therapy.

[55]  K. Bendix,et al.  Is hepatotoxicity in patients treated with gemtuzumabozogamicin due to specific targeting of hepatocytes? , 2011, Leukemia research.

[56]  A. B. Pérez-Oliva,et al.  Epitope mapping, expression and post-translational modifications of two isoforms of CD33 (CD33M and CD33m) on lymphoid and myeloid human cells. , 2011, Glycobiology.

[57]  M. Tallman,et al.  Autologous transplantation gives encouraging results for young adults with favorable-risk acute myeloid leukemia, but is not improved with gemtuzumab ozogamicin. , 2011, Blood.

[58]  E. Rieber,et al.  Simultaneous engagement of the activatory receptors NKG2D and CD3 for retargeting of effector cells to CD33-positive malignant cells , 2011, Leukemia.

[59]  R. Hills,et al.  Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  B. Löwenberg,et al.  Therapeutic advances in acute myeloid leukemia. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  P. Crocker,et al.  Evolution of CD33‐related siglecs: regulating host immune functions and escaping pathogen exploitation? , 2011, Immunology.

[62]  D. Saul,et al.  A single-chain triplebody with specificity for CD19 and CD33 mediates effective lysis of mixed lineage leukemia cells by dual targeting , 2011, mAbs.

[63]  A. Lawson,et al.  Cytokine-induced killer cells for cell therapy of acute myeloid leukemia: improvement of their immune activity by expression of CD33-specific chimeric receptors , 2010, Haematologica.

[64]  S. Larson,et al.  Sequential Cytarabine and α-Particle Immunotherapy with Bismuth-213–Lintuzumab (HuM195) for Acute Myeloid Leukemia , 2010, Clinical Cancer Research.

[65]  D. Saul,et al.  A recombinant trispecific single‐chain Fv derivative directed against CD123 and CD33 mediates effective elimination of acute myeloid leukaemia cells by dual targeting , 2010, British journal of haematology.

[66]  A. Mackensen,et al.  Effective Elimination of Acute Myeloid Leukemic Cells by Recombinant Bispecific Antibody Derivatives Directed Against CD33 and CD16 , 2010, Journal of immunotherapy.

[67]  H. Kantarjian,et al.  Circulating CD33 and its clinical value in acute leukemia. , 2010, Experimental hematology.

[68]  Louis M. Weiner,et al.  Monoclonal antibodies: versatile platforms for cancer immunotherapy , 2010, Nature Reviews Immunology.

[69]  H. Döhner,et al.  Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study. , 2010, Blood.

[70]  Carsten Reinhardt,et al.  Bispecific T-cell engaging antibodies for cancer therapy. , 2009, Cancer research.

[71]  T. Bijma,et al.  A novel AML-selective TRAIL fusion protein that is superior to Gemtuzumab Ozogamicin in terms of in vitro selectivity, activity and stability , 2009, Leukemia.

[72]  E. Estey,et al.  Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[73]  B. Wood,et al.  Complete remissions observed in acute myeloid leukemia following prolonged exposure to lintuzumab: a phase 1 trial , 2009, Leukemia & lymphoma.

[74]  A. Venditti,et al.  Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia. , 2008, Cancer treatment reviews.

[75]  Jonathan A. Cooper,et al.  ITIM‐dependent endocytosis of CD33‐related Siglecs: role of intracellular domain, tyrosine phosphorylation, and the tyrosine phosphatases, Shp1 and Shp2 , 2008, Journal of leukocyte biology.

[76]  Jonathan A. Cooper,et al.  Phosphorylated ITIMs Enable Ubiquitylation of an Inhibitory Cell Surface Receptor , 2007, Traffic.

[77]  S. Larson,et al.  Phase I Trial of the Targeted Alpha-Particle Nano-Generator Actinium-225 (225Ac)-HuM195 (Anti-CD33) in Acute Myeloid Leukemia (AML). , 2007 .

[78]  F. Appelbaum,et al.  Radioimmunotherapy and Hematopoietic Cell Transplantation , 2007 .

[79]  F. Mandelli,et al.  Sustained molecular remission after low dose gemtuzumab-ozogamicin in elderly patients with advanced acute promyelocytic leukemia , 2007, Haematologica.

[80]  S. Rutella,et al.  The role of Gemtuzumab Ozogamicin in the treatment of acute myeloid leukemia patients , 2007, Oncogene.

[81]  C. Bennett,et al.  Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project. , 2007, Leukemia research.

[82]  Ajit Varki,et al.  Siglecs and their roles in the immune system , 2007, Nature Reviews Immunology.

[83]  P. Crocker,et al.  Analysis of the CD33-related siglec family reveals that Siglec-9 is an endocytic receptor expressed on subsets of acute myeloid leukemia cells and absent from normal hematopoietic progenitors. , 2007, Leukemia research.

[84]  J. F. Burrows,et al.  CD33 responses are blocked by SOCS3 through accelerated proteasomal-mediated turnover. , 2007, Blood.

[85]  D. Printz,et al.  Expression of the target receptor CD33 in CD34+/CD38−/CD123+ AML stem cells , 2007, European journal of clinical investigation.

[86]  R. Bouabdallah,et al.  High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group , 2007, Leukemia.

[87]  T. Lewis,et al.  SGN-33 Modulates Cytokine and Chemokine Production by Activated Monocytes and Macrophages. , 2006 .

[88]  J. Issa,et al.  Aberrant CpG Island Methylation in AML Is Associated with Disease Progression and Relapse. , 2006 .

[89]  M. Tallman,et al.  Monoclonal antibodies for the treatment of acute myeloid leukemia. , 2006, Current pharmaceutical biotechnology.

[90]  A. B. Pérez-Oliva,et al.  A study of CD33 (SIGLEC‐3) antigen expression and function on activated human T and NK cells: two isoforms of CD33 are generated by alternative splicing , 2006, Journal of leukocyte biology.

[91]  H. Kantarjian,et al.  The role of gemtuzumab ozogamicin in acute leukaemia therapy , 2005, British journal of haematology.

[92]  A. Varki,et al.  Siglecs--the major subfamily of I-type lectins. , 2006, Glycobiology.

[93]  T. Lister,et al.  Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia. , 2005, Blood.

[94]  I. Bernstein,et al.  Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33‐positive acute myeloid leukemia in first recurrence , 2005, Cancer.

[95]  D. Scheinberg,et al.  Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[96]  T. Kalina,et al.  Correlation of CD33 with poorer prognosis in childhood ALL implicates a potential of anti-CD33 frontline therapy , 2005, Leukemia.

[97]  M. Linenberger,et al.  CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance , 2005, Leukemia.

[98]  J. Dayer,et al.  Constitutive repressor activity of CD33 on human monocytes requires sialic acid recognition and phosphoinositide 3‐kinase‐mediated intracellular signaling , 2005, European journal of immunology.

[99]  Jonathan A. Cooper,et al.  Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin-induced cytotoxicity. , 2004, Blood.

[100]  S. Larson,et al.  Sequential Therapy with Cytarabine and Bismuth-213 (213Bi)-Labeled-HuM195 (Anti-CD33) for Acute Myeloid Leukemia (AML). , 2004 .

[101]  F. Mandelli,et al.  Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia. , 2004, Blood.

[102]  E. Estey,et al.  Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia , 2003, Cancer.

[103]  E. Paietta,et al.  Expression of cell-surface antigens in acute promyelocytic leukaemia. , 2003, Best practice & research. Clinical haematology.

[104]  P. Richardson,et al.  Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. , 2003, Blood.

[105]  P. Frost,et al.  Antibody-targeted chemotherapy with immunoconjugates of calicheamicin. , 2003, Current opinion in pharmacology.

[106]  D. Reinhardt,et al.  Gemtuzumab ozogamicin in pediatric CD33-positive acute lymphoblastic leukemia: first clinical experiences and relation with cellular sensitivity to single agent calicheamicin , 2003, Leukemia.

[107]  D. Scheinberg,et al.  Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-CD33 monoclonal antibody HuM195 , 2003, Leukemia.

[108]  J. Burke,et al.  Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias , 2003, Bone Marrow Transplantation.

[109]  H. Kantarjian,et al.  Differences in CD33 intensity between various myeloid neoplasms. , 2002, American journal of clinical pathology.

[110]  J. Humm,et al.  Targeted α particle immunotherapy for myeloid leukemia , 2002 .

[111]  E. Estey,et al.  Experience with gemtuzumab ozogamycin ("mylotarg") and all-trans retinoic acid in untreated acute promyelocytic leukemia. , 2002, Blood.

[112]  G. McDonald,et al.  Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy. , 2002, Blood.

[113]  G. Yousef,et al.  Genomic organization of the siglec gene locus on chromosome 19q13.4 and cloning of two new siglec pseudogenes. , 2002, Gene.

[114]  G. McDonald.  Management of hepatic sinusoidal obstruction syndrome following treatment with gemtuzumab ozogamicin (Mylotarg). , 2002, Clinical lymphoma.

[115]  R. Silver,et al.  Efficacy and Safety of Gemtuzumab Ozogamicin in Patients with Poor-prognosis Acute Myeloid Leukemia , 2002, Leukemia & lymphoma.

[116]  P. Carter,et al.  Improving the efficacy of antibody-based cancer therapies , 2001, Nature Reviews Cancer.

[117]  F. Mandelli,et al.  Prolonged molecular remission in advanced acute promyelocytic leukaemia after treatment with gemtuzumab ozogamicin (MylotargTM CMA‐676) , 2001, British journal of haematology.

[118]  E. Estey,et al.  Mylotarg™ (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation , 2001, Cancer.

[119]  I. Bernstein,et al.  Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[120]  X. H. Chen,et al.  Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[121]  I. Bernstein,et al.  Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. , 2001, Blood.

[122]  D. Olive,et al.  Surface expression and function of p75/AIRM-1 or CD33 in acute myeloid leukemias: Engagement of CD33 induces apoptosis of leukemic cells , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[123]  D. McVicar,et al.  Myeloid specific human CD33 is an inhibitory receptor with differential ITIM function in recruiting the phosphatases SHP-1 and SHP-2. , 2000, Blood.

[124]  I. Bernstein.  Monoclonal antibodies to the myeloid stem cells: therapeutic implications of CMA-676, a humanized anti-CD33 antibody calicheamicin conjugate , 2000, Leukemia.

[125]  D. Scheinberg,et al.  Molecular remission induction with retinoic acid and anti-CD33 monoclonal antibody HuM195 in acute promyelocytic leukemia. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[126]  L. Moretta,et al.  Engagement of p75/AIRM1 or CD33 inhibits the proliferation of normal or leukemic myeloid cells. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[127]  Matthew L. Thomas,et al.  The sialoadhesin CD33 is a myeloid‐specific inhibitory receptor , 1999, European journal of immunology.

[128]  S. Larson,et al.  Preparation of α-Emitting 213Bi-Labeled Antibody Constructs for Clinical Use , 1999 .

[129]  Wan Ariffin Bin Abdullah,et al.  Med Pediatr Oncol , 1999 .

[130]  I. Bernstein,et al.  CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Selective Ablation of Acute Myeloid Leukemia Using Antibody-Targeted Chemotherapy: A Phase I Study of an Anti-CD33 Calicheamicin Immunoconjugate , 2017 .

[131]  C. Buckley,et al.  The Myeloid-specific Sialic Acid-binding Receptor, CD33, Associates with the Protein-tyrosine Phosphatases, SHP-1 and SHP-2* , 1999, The Journal of Biological Chemistry.

[132]  H. Yazıcı,et al.  Phenotypic characteristics of B cells in Behçet's disease: increased activity in B cell subsets. , 1999, The Journal of rheumatology.

[133]  D. Scheinberg,et al.  Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity and chemistry. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[134]  D. Printz,et al.  Four-color flow cytometric investigation of terminal deoxynucleotidyl transferase-positive lymphoid precursors in pediatric bone marrow: CD79a expression precedes CD19 in early B-cell ontogeny. , 1998, Blood.

[135]  G. Avvisati,et al.  Immunophenotype of adult and childhood acute promyelocytic leukaemia: correlation with morphology, type of PML gene breakpoint and clinical outcome. A cooperative Italian study on 196 cases , 1998, British journal of haematology.

[136]  K. Sullivan,et al.  Long-Term Follow-Up of a Randomized Trial of Two Irradiation Regimens for Patients Receiving Allogeneic Marrow Transplants During First Remission of Acute Myeloid Leukemia , 1998 .

[137]  D. Scheinberg,et al.  Supersaturating infusional humanized anti-CD33 monoclonal antibody HuM195 in myelogenous leukemia. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[138]  M. Toribio,et al.  Identification of a common developmental pathway for thymic natural killer cells and dendritic cells. , 1998, Blood.

[139]  I. Bernstein,et al.  Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells. , 1996, Cancer research.

[140]  B. Drénou,et al.  Internalization of human macrophage surface antigens induced by monoclonal antibodies. , 1995, Journal of immunological methods.

[141]  S. Larson,et al.  Radiolabeled anti-CD33 monoclonal antibody M195 for myeloid leukemias. , 1995, Cancer research.

[142]  D. Huhn,et al.  Propagation of large numbers of cells of a human mixed‐lineage T‐lymphoid/myeloid , 1995, British journal of haematology.

[143]  P. Crocker,et al.  Characterization of CD33 as a new member of the sialoadhesin family of cellular interaction molecules. , 1995, Blood.

[144]  A. Scott,et al.  A phase 1B trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: specific targeting without immunogenicity , 1994 .

[145]  Y. Nakamura,et al.  Expression of CD33 antigen on normal human activated T lymphocytes. , 1994, Blood.

[146]  R. Andrews,et al.  Isolation of human hematopoietic stem cells. , 1994, Blood cells.

[147]  R. Handgretinger,et al.  Expression of an early myelopoietic antigen (CD33) on a subset of human umbilical cord blood-derived natural killer cells. , 1993, Immunology letters.

[148]  M. Andreeff,et al.  Dose-escalation trial of M195 labeled with iodine 131 for cytoreduction and marrow ablation in relapsed or refractory myeloid leukemias. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[149]  D. Scheinberg,et al.  Biological and immunological features of humanized M195 (anti-CD33) monoclonal antibodies. , 1992, Cancer research.

[150]  I. Bernstein,et al.  THE USE OF RADIOLABELED ANTI‐CD33 ANTIBODY TO AUGMENT MARROW IRRADIATION PRIOR TO MARROW TRANSPLANTATION FOR ACUTE MYELOGENOUS LEUKEMIA , 1992, Transplantation.

[151]  J. Ritz,et al.  Human bone marrow depleted of CD33-positive cells mediates delayed but durable reconstitution of hematopoiesis: clinical trial of MY9 monoclonal antibody-purged autografts for the treatment of acute myeloid leukemia. , 1992, Blood.

[152]  M. Cutting,et al.  Effects of anti-CD33 blocked ricin immunotoxin on the capacity of CD34+ human marrow cells to establish in vitro hematopoiesis in long-term marrow cultures. , 1992, Experimental hematology.

[153]  I. Bernstein,et al.  Differences in the frequency of normal and clonal precursors of colony- forming cells in chronic myelogenous leukemia and acute myelogenous leukemia , 1992 .

[154]  I. Bernstein,et al.  Expression of myeloid differentiation antigens in acute nonlymphocytic leukemia: increased concentration of CD33 antigen predicts poor outcome--a report from the Childrens Cancer Study Group. , 1992, Medical and pediatric oncology.

[155]  I. Bernstein,et al.  Localization of radiolabeled antimyeloid antibodies in a human acute leukemia xenograft tumor model. , 1992, Cancer research.

[156]  D. Scheinberg,et al.  A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone marrow targeting and internalization of radionuclide. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[157]  F. Appelbaum,et al.  Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. , 1990, Blood.

[158]  D. Scheinberg,et al.  Monoclonal antibody M195: a diagnostic marker for acute myelogenous leukemia. , 1989, Leukemia.

[159]  C. Cordon-Cardo,et al.  Restricted expression of an early myeloid and monocytic cell surface antigen defined by monoclonal antibody M195. , 1989, Leukemia.

[160]  I. Bernstein,et al.  Precursors of colony-forming cells in humans can be distinguished from colony-forming cells by expression of the CD33 and CD34 antigens and light scatter properties , 1989, The Journal of experimental medicine.

[161]  B. Seed,et al.  Isolation of a cDNA encoding CD33, a differentiation antigen of myeloid progenitor cells. , 1988, Journal of immunology.

[162]  J. Adamson,et al.  Clonal development, stem-cell differentiation, and clinical remissions in acute nonlymphocytic leukemia. , 1987, The New England journal of medicine.

[163]  I. Bernstein,et al.  Treatment of acute myeloid leukemia cells in vitro with a monoclonal antibody recognizing a myeloid differentiation antigen allows normal progenitor cells to be expressed. , 1987, The Journal of clinical investigation.

[164]  I. Bernstein,et al.  The L4F3 antigen is expressed by unipotent and multipotent colony-forming cells but not by their precursors. , 1986, Blood.

[165]  J. Griffin,et al.  A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells. , 1984, Leukemia research.

[166]  I. Bernstein,et al.  Myeloid-associated differentiation antigens on stem cells and their progeny identified by monoclonal antibodies , 1983 .

[167]  J. Adamson,et al.  Acute nonlymphocytic leukemia: heterogeneity of stem cell origin. , 1981, Blood.

[168]  R Storb,et al.  Bone-marrow transplantation (first of two parts). , 1975, The New England journal of medicine.